Prescribing in COVID-19 patients: Should we take into account inflammation?
- PMID: 32820554
- DOI: 10.1111/bcp.14524
Prescribing in COVID-19 patients: Should we take into account inflammation?
Keywords: COVID-19; drug-drug interactions; inflammation; inhibition drug metabolism.
References
REFERENCES
-
- Fedson DS, Opal SM, Rordam OM. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. mBio. 2020;11:e00398-20. [PMID: 32198163]. https://doi.org/10.1128/mBio.00398-20
-
- Martin JH, Clark J, Head R. Buying time: drug repurposing to treat the host in COVID-19H. Pharmacol Res Perspect. 2020;8(4):e00620. [PMID: 32578336]. https://doi.org/10.1002/prp2.620
-
- Baker EH, Gnjidic D, Kirkpatrick CMJ, Pirmohamed M, Wright DFB, Zecharia AY. A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments. Br J Clin Pharmacol. 2020[epub ahead of print]. [PMID: 32515023]. https://doi.org/10.1111/bcp.14416
-
- Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36(2):205-216. [PMID: 18218849]. https://doi.org/10.1124/dmd.107.018747
-
- Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos. 2011;39(8):1415-1422. [PMID: 21555507]. https://doi.org/10.1124/dmd.111.038679
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical